The expiration of primary patents on high-value therapeutics, frequently termed the patent cliff, creates a predictable revenue vacuum for innovators. […]
Real World Blockchain Uses in the Pharmaceutical Industry Read Post »
The Architecture of Resilience: A Comprehensive Analysis of Premarin’s Sustained Market Dominance Without Patent Protection The pharmaceutical industry operates on
How Premarin Maintained Market Dominance Without Patent Protection Read Post »
Patent opposition is where pharma IP stops being administrative paperwork and starts functioning as competitive strategy. A single successful opposition
There is a persistent myth in the pharmaceutical industry that generic drug development is a reduced-complexity, paint-by-numbers exercise. You take
Generic Drug Clinical Studies: The Complete ANDA Playbook for Bioequivalence Success Read Post »
1. Why Generic Defense Requires a Ten-Year Lead Time The time to begin planning for generic competition is the day
The pharmaceutical company that treats its patent portfolio as a legal filing system is the one that gets ambushed at
Section 1: The Deal Beneath the Deal: Why Licensing Structure Reveals Strategic Intent A pharmaceutical patent licensing agreement is not
I. Executive Summary and Key Takeaways Patient advocacy groups (PAGs) have crossed a threshold. They are no longer peripheral voices
Executive Summary Chiral switching built billion-dollar franchises in the 1990s and early 2000s. The model was straightforward: isolate the active
Chiral Switching Is Dead as a Patent Play. Here’s Where It Still Makes Money. Read Post »
Sign in or create a free account to read this DrugPatentWatch article
